Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pancreatic Neoplasms 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × Ultrasonography × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡